CD276, CD276 molecule, 80381

N. diseases: 169; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.350 Biomarker disease BEFREE Taken together, these results indicated that B7‑H2‑ and/or B7‑H3‑positive expression indicates a poor clinical outcome for patients, and the combination of B7‑H2 and B7‑H3 may be a preferential prognostic biomarker in patients with HCC. 30942404 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.350 Biomarker disease BEFREE Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3. 28243980 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.350 Biomarker disease BEFREE Involvement of soluble B7-H3 in combination with the serum inflammatory cytokines interleukin-17, -8 and -6 in the diagnosis of hepatocellular carcinoma. 29344257 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.350 AlteredExpression disease BEFREE In this study, we investigated the expression of B7-H3 in tissues and cells of primary hepatocellular carcinoma (PHC) patients. 24787022 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.350 Biomarker disease BEFREE Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3. 16217749 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.350 Therapeutic disease CTD_human Large subcutaneous H22 HCCs (0.7-0.8 cm in diameter) established in BALB/c mice were rapidly and completely eradicated when intratumoral administration of As(2)O(3) was preceded by in situ gene transfer of B7H3. 16217749 2006